Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Tabor City, NC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Tabor City, NC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Marion, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Marion, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Zanesville, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Zanesville, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Eugene, OR
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Philadelphia, PA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Warwick, RI
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Warwick, RI
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigational Site
mi
from
Charleston, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Columbia, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Columbia, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Greer, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Greer, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
N. Myrtle Beach, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
N. Myrtle Beach, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Boerne, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Boerne, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
El Paso, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
El Paso, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Kingwood, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Kingwood, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis
mi
from
San Antonio, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
White River Junction, VT
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
White River Junction, VT
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Burke, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Burke, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Fredericksburg, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Manassas, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Manassas, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Oregon, WI
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Oregon, WI
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Greenville, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated:  2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated: 2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD
Status: Enrolling
Updated:  2/24/2016
Novartis Investigative Site
mi
from
Richmond, VA
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD
Status: Enrolling
Updated: 2/24/2016
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD
Status: Enrolling
Updated:  2/24/2016
Novartis Investigative Site
mi
from
Berlin,
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD
Status: Enrolling
Updated: 2/24/2016
Novartis Investigative Site
mi
from
Berlin,
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Vestavia, AL
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Vestavia, AL
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Huntington Beach, CA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Lakewood, CA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Lakewood, CA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative site
mi
from
Los Angeles, CA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigational Site
mi
from
Orange, CA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Stockton, CA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Stockton, CA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Walnut Creek, CA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Boulder, CO
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Boulder, CO
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Honolulu, HI
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Lombard, IL
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Lombard, IL
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
O'Fallon, IL
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
O'Fallon, IL
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Peoria, IL
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Peoria, IL
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigator Site
mi
from
Evansville, IN
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Ames, IA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Ames, IA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigator Site
mi
from
Iowa City, IA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigator Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Waterloo, IA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Waterloo, IA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Bowling Green, KY
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Bowling Green, KY
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
New Orleans, LA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Slidell, LA
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Slidell, LA
Click here to add this to my saved trials
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/29/2016
Novartis Investigative Site
mi
from
Bangor, ME
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/29/2016
Novartis Investigative Site
mi
from
Bangor, ME
Click here to add this to my saved trials